A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome ® in Healthy Subjects
Condition: Bioequivalence Interventions: Drug: Amphotericin B liposome for injection; Drug: AmBisome® Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials